In a phase 3 study that randomized patients with ALK-rearranged NSCLC to alectinib vs. crizotinib, the CNS response rate and median duration of response for patients with baseline CNS metastases was 81% and 17.3 months, vs. 50% and 5.5 months, for alectinib vs. crizotinib, respectively (17). The gene discussed is ALK; the disease is non-small cell lung carcinoma.